Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.61 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5940017 | 0.89 | HTT (0.62) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL864629 | 0.84 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL27922741 | 0.83 | CHRM2 (0.62) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL1202552 | 0.82 | HTT (0.61) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL28805745 | 0.81 | CHRM2 (0.66) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL13618029 | 0.81 | S1PR1 (0.60) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL5300649 | 0.81 | CHRM2 (0.61) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL15694807 | 0.79 | ALDH1A1 (0.67) | HDAC3HDAC1HDAC2HDAC8CHRM2 | |
| SCHEMBL3669498 | 0.79 | ALDH1A1 (0.56) | HDAC3HDAC1HDAC2HDAC8S1PR1 | |
| SCHEMBL10045186 | 0.79 | CHRM2 (0.88) | HDAC3HDAC1HDAC2HDAC8CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196453-A1 | Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents | Cellvir (FR) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | HDAC3 948/4885HDAC1 1056/4885HDAC2 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.